Exelixis has a history of productive drug discovery, and we have partnered multiple compounds and programs with leading pharmaceutical and biopharmaceutical companies, including Bristol-Myers Squibb Company, Daiichi-Sankyo Company Limited, Genentech (a member of the Roche Group), Ipsen, Merck (known as MSD outside of the United States and Canada), and Sanofi. These collaborations cover a variety of compounds and programs with potential for use in the treatment of cancer, inflammation, and cardiovascular and metabolic diseases.